03:08 PM EDT, 06/25/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Tuesday it plans to advance its investigational medicine plozasiran into a late-stage cardiovascular study.

The phase 3 Capitan trial will enroll patients with residual risk of atherosclerotic cardiovascular disease and mixed hyperlipidemia, a condition characterized by high levels of fats in the blood, the drugmaker said.

Arrowhead said its other investigational cardiometabolic drug, zodasiran, also achieved "highly encouraging results" but that it will only conduct further development if it identifies a "suitable development and commercialization partner."

Price: 27.26, Change: +0.02, Percent Change: +0.06